Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
03/20/20177:05AMGLOBEMyriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical Genetics Annual Clinical Gene...
SALT LAKE CITY, March 20, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company will present five scientific posters at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting in Phoenix, AZ. ... More...>>
03/13/20177:05AMGLOBEMyriad Genetics Launches the EndoPredict® Test in the United States for Patients with Breast Cancer
SALT LAKE CITY, March 13, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has launched the EndoPredict® test in the United States for patients with ER+ HER2- early-stage breast cancer.  EndoPredict is a second-generation... More...>>
02/23/20177:05AMGLOBEGeneSight® Psychotropic Test Demonstrated Substantial Cost Savings for Payers in New Study Published in Clinical Therapeutic...
SALT LAKE CITY, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of the GeneSight® Psychotropic test to deliver medication cost savings for mental health disorders was published in the journal Clinical Therapeutics.[1] ... More...>>
02/17/20177:30AMGLOBEMyriad’s BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with Improved Outcomes from Astr...
SALT LAKE CITY, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new findings from the OlympiAD study that show its BRACAnalysis CDx®  test successfully identified patients with HER2-negative metastatic breast cancer... More...>>
02/17/20177:05AMGLOBEMyriad’s Prolaris® Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prost...
SALT LAKE CITY, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to more accurately classify mortality risk and guide the management of newly diagnosed men with prostate cancer. The... More...>>
02/10/20175:47PMPRNUSMyriad Genetics to Join S&P SmallCap 600
Myriad Genetics to Join S&P SmallCap 600 PR Newswire NEW YORK, Feb. 10, 2017 NEW YORK, Feb. 10, 2017 /PRNewswire/ -- Myriad Genetics, Inc. (NASD: MYGN) will replace Inteliquent, Inc. (NASD: IQNT) in the S&P SmallCap 600 after the close on Tuesday, February 14. GTCR LLC has acquired Inteliquent in a deal expected... More...>>
02/07/20174:05PMGLOBEMyriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results
Second-Quarter 2017 Total Revenues of $196.5 MillionSecond-Quarter 2017 GAAP Diluted EPS of $0.09 and Adjusted EPS of $0.26Company Updates Fiscal Year 2017 Guidance and Issues Fiscal Third-Quarter 2017 Guidance SALT LAKE CITY, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular... More...>>
01/24/20174:05PMGLOBEMyriad to Announce Fiscal Second-Quarter 2017 Financial Results on February 7, 2017
SALT LAKE CITY, Jan. 24, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, February 7, 2017.  During the call, Mark C. Capone, president and CEO and... More...>>
01/06/20177:05AMGLOBEThe EndoPredict® Test Receives Positive Coverage Decisions from Multiple Blue Cross Blue Shield Affiliate Plans
SALT LAKE CITY, Jan. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced that multiple Blue Cross Blue Shield (BCBS) affiliate plans have issued positive coverage determinations for EndoPredict®, including Independence Blue Cross, Blue Cross and Blue... More...>>
01/05/20177:05AMGLOBEEndoPredict® Reviewed by Blue Cross Blue Shield Association’s Evidence Street
SALT LAKE CITY, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced that Evidence Street has reviewed EndoPredict®, Myriad’s second-generation test to predict breast cancer recurrence, and determined that the test results in a meaningful improvement... More...>>
12/28/20167:05AMGLOBEMyriad Genetics to Present at the 2017 JP Morgan Healthcare Conference
SALT LAKE CITY, Dec. 28, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2017 JP Morgan Healthcare Conference at 6:00 p.m. ET on January 9, 2017, at the Westin St. Francis Hotel in San Francisco, California... More...>>
12/27/20167:05AMGLOBEPositive Clinical Utility Results of Crescendo’s Vectra® DA Test for Rheumatoid Arthritis Published in the Journal Arthrit...
SALT LAKE CITY, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra® DA test to predict treatment response in patients with rheumatoid arthritis (RA) published online in the journal Arthritis &... More...>>
12/22/20162:03PMGLOBEUnited Rheumatology Issues Clinical Practice Guidelines and Recommends the Vectra® DA Test for Adults with Rheumatoid Arthri...
SALT LAKE CITY, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that United Rheumatology, a leading professional organization for rheumatologists in the United States with more that 300 members, has added Vectra® DA to its clinical... More...>>
12/09/20167:05AMGLOBEThe EndoPredict® Test Significantly Outperforms the First-Generation Test in Predicting the Risk of Node-Negative and Node-P...
SALT LAKE CITY, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results of a large head-to-head study comparing the efficacy of six tests used to predict the recurrence of breast cancer.  A key finding was that EndoPredict®... More...>>
11/28/20167:05AMGLOBEMyriad Genetics Will Present Results from Six Breast Cancer Studies at SABCS
SALT LAKE CITY, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the Company will present six breast cancer studies at the 2016 San Antonio Breast Cancer Symposium (SABCS) being held Dec. 6-10, 2016 in San Antonio, Texas... More...>>
11/12/20164:30PMGLOBECrescendo Bioscience Announces Four Studies with Vectra® DA Will Be Presented at the American College of Rheumatology 2016 A...
SALT LAKE CITY, Nov. 12, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that four poster presentations on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 11-16, 2016 in Washington, D.C.  ... More...>>
11/07/20167:05AMGLOBEMyriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx®
SALT LAKE CITY, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will submit its BRACAnalysis CDx® test for approval by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in parallel with the PMDA review... More...>>
11/04/20167:05AMGLOBEThe GeneSight® Precision Medicine Test Drives Significant Medication Cost Savings in Patients with Generalized Anxiety Disor...
SALT LAKE CITY, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that a poster featuring the GeneSight® test will be presented at the Neuroscience Education Institute (NEI) Psychopharmacology Congress being held Nov. 3-6, 2016 in Colorado... More...>>
11/01/20164:05PMGLOBEMyriad Genetics Reports Fiscal First-Quarter 2017 Financial Results
Total Revenues of $177.5 MillionAdjusted EPS of $0.23 and Diluted EPS of ($0.02)Company Maintains Fiscal Year 2017 Financial Guidance and Issues Fiscal Second-Quarter 2017 Financial Guidance SALT LAKE CITY, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced financial results for its fiscal... More...>>
10/27/20167:05AMGLOBEThe Myriad myPath® Melanoma Test Effectively Diagnosed Patients in the Largest Outcomes-Based Study for a Melanoma Diagnosti...
SALT LAKE CITY, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present two new studies at the American Society of Dermatopathology (ASDP) annual meeting being held Oct. 27-30, 2016 in Chicago, Ill.  The research... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V:us D:20170327 12:45:47